Boston Scientific Corporation (NYSE: BSX) Stock Competitors & Peer Comparison

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ABT trades at $107.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ABT's P/E ratio is 20.69. In terms of profitability, BSX's ROE is +0.15%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BSX is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ABT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BSX's ROE is +0.15%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BSX is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BSX-PA's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SYK has a market cap of 130B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SYK trades at $339.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SYK's P/E ratio is 25.32. In terms of profitability, BSX's ROE is +0.15%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BSX is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SYK's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, MDT has a market cap of 111.6B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while MDT trades at $87.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas MDT's P/E ratio is 15.76. In terms of profitability, BSX's ROE is +0.15%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BSX is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check MDT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while EW trades at $89.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas EW's P/E ratio is 33.23. In terms of profitability, BSX's ROE is +0.15%, compared to EW's ROE of +0.10%. Regarding short-term risk, BSX is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BSX.Check EW's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, DXCM has a market cap of 32B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while DXCM trades at $84.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas DXCM's P/E ratio is 36.37. In terms of profitability, BSX's ROE is +0.15%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BSX is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check DXCM's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, RMD has a market cap of 30.7B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while RMD trades at $211.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas RMD's P/E ratio is 19.68. In terms of profitability, BSX's ROE is +0.15%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BSX is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check RMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PHG trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PHG's P/E ratio is 15.28. In terms of profitability, BSX's ROE is +0.15%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BSX is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BSX.Check PHG's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ZBH trades at $96.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ZBH's P/E ratio is 11.38. In terms of profitability, BSX's ROE is +0.15%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BSX is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ZBH's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BSX's ROE is +0.15%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BSX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ABMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PEN trades at $324.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PEN's P/E ratio is 84.77. In terms of profitability, BSX's ROE is +0.15%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BSX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BSX.Check PEN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SNN trades at $30.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SNN's P/E ratio is 14.16. In terms of profitability, BSX's ROE is +0.15%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BSX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SNN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BSX's ROE is +0.15%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BSX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SWAV's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ALGN trades at $173.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ALGN's P/E ratio is 15.83. In terms of profitability, BSX's ROE is +0.15%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, BSX is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ALGN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while GMED trades at $82.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas GMED's P/E ratio is 18.56. In terms of profitability, BSX's ROE is +0.15%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for BSX.Check GMED's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while GKOS trades at $180.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas GKOS's P/E ratio is -209.45. In terms of profitability, BSX's ROE is +0.15%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BSX is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check GKOS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PODD trades at $141.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PODD's P/E ratio is 24.05. In terms of profitability, BSX's ROE is +0.15%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BSX is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PODD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BIO-B trades at $349.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, BSX's ROE is +0.15%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BSX is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BSX.Check BIO-B's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BIO trades at $352.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BIO's P/E ratio is 38.00. In terms of profitability, BSX's ROE is +0.15%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BSX is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BIO's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas MASI's P/E ratio is 44.43. In terms of profitability, BSX's ROE is +0.15%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BSX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BSX.Check MASI's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BRKR trades at $53.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BRKR's P/E ratio is 26.84. In terms of profitability, BSX's ROE is +0.15%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BSX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BRKR's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas NARI's P/E ratio is -59.24. In terms of profitability, BSX's ROE is +0.15%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BSX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BSX.Check NARI's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ITGR trades at $125.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ITGR's P/E ratio is 19.72. In terms of profitability, BSX's ROE is +0.15%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BSX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ITGR's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while IRTC trades at $127.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas IRTC's P/E ratio is -199.75. In terms of profitability, BSX's ROE is +0.15%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BSX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BSX.Check IRTC's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while LIVN trades at $76.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas LIVN's P/E ratio is 18.10. In terms of profitability, BSX's ROE is +0.15%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BSX is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check LIVN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, HAE has a market cap of 4B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while HAE trades at $87.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas HAE's P/E ratio is 17.54. In terms of profitability, BSX's ROE is +0.15%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BSX is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BSX.Check HAE's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BSX's ROE is +0.15%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BSX is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BSX.Check AXNX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while TMDX trades at $83.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas TMDX's P/E ratio is 42.58. In terms of profitability, BSX's ROE is +0.15%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BSX is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TMDX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while AXGN trades at $46.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas AXGN's P/E ratio is 122.18. In terms of profitability, BSX's ROE is +0.15%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BSX is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AXGN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while UFPT trades at $314.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas UFPT's P/E ratio is 32.07. In terms of profitability, BSX's ROE is +0.15%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BSX is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check UFPT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BFLY trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BFLY's P/E ratio is -36.77. In terms of profitability, BSX's ROE is +0.15%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BSX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BFLY's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ESTA trades at $77.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ESTA's P/E ratio is -61.44. In terms of profitability, BSX's ROE is +0.15%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BSX is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ESTA's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BSX's ROE is +0.15%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BSX is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NUVA's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while NVCR trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas NVCR's P/E ratio is -10.71. In terms of profitability, BSX's ROE is +0.15%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BSX is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NVCR's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while INSP trades at $60.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas INSP's P/E ratio is 26.51. In terms of profitability, BSX's ROE is +0.15%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BSX is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BSX.Check INSP's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while TNDM trades at $22.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas TNDM's P/E ratio is -20.35. In terms of profitability, BSX's ROE is +0.15%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BSX is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TNDM's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ENOV trades at $26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ENOV's P/E ratio is 7.62. In terms of profitability, BSX's ROE is +0.15%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BSX is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ENOV's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CNMD trades at $49.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CNMD's P/E ratio is 10.78. In terms of profitability, BSX's ROE is +0.15%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BSX is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CNMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ATEC trades at $9.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ATEC's P/E ratio is -155.17. In terms of profitability, BSX's ROE is +0.15%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BSX is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ATEC's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while IART trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas IART's P/E ratio is 7.31. In terms of profitability, BSX's ROE is +0.15%, compared to IART's ROE of -0.01%. Regarding short-term risk, BSX is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BSX.Check IART's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while AORT trades at $27.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas AORT's P/E ratio is 45.28. In terms of profitability, BSX's ROE is +0.15%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BSX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AORT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BSX's ROE is +0.15%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BSX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BSX.Check HSKA's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while IRMD trades at $92.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas IRMD's P/E ratio is 46.48. In terms of profitability, BSX's ROE is +0.15%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BSX is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for BSX.Check IRMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BSX's ROE is +0.15%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BSX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BSX.Check AVNS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PRCT trades at $20.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PRCT's P/E ratio is -10.52. In terms of profitability, BSX's ROE is +0.15%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BSX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PRCT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SILK's P/E ratio is -18.96. In terms of profitability, BSX's ROE is +0.15%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BSX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SILK's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while LMRI trades at $11.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas LMRI's P/E ratio is -22.53. In terms of profitability, BSX's ROE is +0.15%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BSX is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check LMRI's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas FNA's P/E ratio is -19.83. In terms of profitability, BSX's ROE is +0.15%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BSX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BSX.Check FNA's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BVS has a market cap of 956.9M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BVS trades at $14.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BVS's P/E ratio is 18.59. In terms of profitability, BSX's ROE is +0.15%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BSX is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BVS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, INMD has a market cap of 880M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while INMD trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas INMD's P/E ratio is 10.63. In terms of profitability, BSX's ROE is +0.15%, compared to INMD's ROE of +0.13%. Regarding short-term risk, BSX is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BSX.Check INMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while AVR trades at $8.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas AVR's P/E ratio is -4.00. In terms of profitability, BSX's ROE is +0.15%, compared to AVR's ROE of -1.24%. Regarding short-term risk, BSX is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AVR's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CSII's P/E ratio is -20.83. In terms of profitability, BSX's ROE is +0.15%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BSX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BSX.Check CSII's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SIBN has a market cap of 825.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SIBN trades at $18.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SIBN's P/E ratio is -54.74. In terms of profitability, BSX's ROE is +0.15%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BSX is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SIBN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, AHCO has a market cap of 774.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while AHCO trades at $5.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas AHCO's P/E ratio is 11.61. In terms of profitability, BSX's ROE is +0.15%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BSX is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BSX.Check AHCO's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SSII has a market cap of 754.5M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SSII trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SSII's P/E ratio is -73.53. In terms of profitability, BSX's ROE is +0.15%, compared to SSII's ROE of -0.23%. Regarding short-term risk, BSX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SSII's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BBNX has a market cap of 715.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BBNX trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BBNX's P/E ratio is -10.53. In terms of profitability, BSX's ROE is +0.15%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BSX is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BBNX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CBLL has a market cap of 713.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CBLL trades at $18.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CBLL's P/E ratio is -11.54. In terms of profitability, BSX's ROE is +0.15%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, BSX is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CBLL's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, TCMD has a market cap of 665.4M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while TCMD trades at $29.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas TCMD's P/E ratio is 33.52. In terms of profitability, BSX's ROE is +0.15%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, BSX is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TCMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BSX's ROE is +0.15%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BSX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SRDX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BWAY has a market cap of 608M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BWAY trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BWAY's P/E ratio is 39.38. In terms of profitability, BSX's ROE is +0.15%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, BSX is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BWAY's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, KIDS has a market cap of 584.8M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while KIDS trades at $22.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas KIDS's P/E ratio is -19.30. In terms of profitability, BSX's ROE is +0.15%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BSX is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check KIDS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas APEN's P/E ratio is -9.43. In terms of profitability, BSX's ROE is +0.15%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BSX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BSX.Check APEN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CTKB has a market cap of 542.4M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CTKB trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CTKB's P/E ratio is -22.25. In terms of profitability, BSX's ROE is +0.15%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BSX is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CTKB's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BSX's ROE is +0.15%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BSX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ZIMV's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, VREX has a market cap of 522.5M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while VREX trades at $12.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas VREX's P/E ratio is 13.06. In terms of profitability, BSX's ROE is +0.15%, compared to VREX's ROE of -0.18%. Regarding short-term risk, BSX is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check VREX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, DCTH has a market cap of 521.6M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while DCTH trades at $15.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas DCTH's P/E ratio is 1511.00. In terms of profitability, BSX's ROE is +0.15%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BSX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BSX.Check DCTH's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, NPCE has a market cap of 505.6M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while NPCE trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas NPCE's P/E ratio is -25.57. In terms of profitability, BSX's ROE is +0.15%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, BSX is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BSX.Check NPCE's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CERS has a market cap of 473.6M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CERS trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CERS's P/E ratio is -46.91. In terms of profitability, BSX's ROE is +0.15%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BSX is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CERS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CLPT has a market cap of 426.2M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CLPT trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CLPT's P/E ratio is -12.04. In terms of profitability, BSX's ROE is +0.15%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BSX is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CLPT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, OFIX has a market cap of 415.5M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while OFIX trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas OFIX's P/E ratio is -13.43. In terms of profitability, BSX's ROE is +0.15%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BSX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check OFIX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SGHT has a market cap of 406.4M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SGHT trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SGHT's P/E ratio is -13.34. In terms of profitability, BSX's ROE is +0.15%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BSX is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SGHT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CARL has a market cap of 375.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CARL trades at $13.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CARL's P/E ratio is -9.66. In terms of profitability, BSX's ROE is +0.15%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BSX is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CARL's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PACB has a market cap of 368.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PACB trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PACB's P/E ratio is -2.89. In terms of profitability, BSX's ROE is +0.15%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BSX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PACB's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CV has a market cap of 354.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CV trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CV's P/E ratio is -2.84. In terms of profitability, BSX's ROE is +0.15%, compared to CV's ROE of +1.27%. Regarding short-term risk, BSX is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CV's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PMI trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PMI's P/E ratio is -2.83. In terms of profitability, BSX's ROE is +0.15%, compared to PMI's ROE of +4.99%. Regarding short-term risk, BSX is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PMI's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ELMD has a market cap of 348.5M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ELMD trades at $42.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ELMD's P/E ratio is 35.97. In terms of profitability, BSX's ROE is +0.15%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BSX is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ELMD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while CATX trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas CATX's P/E ratio is -2.13. In terms of profitability, BSX's ROE is +0.15%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BSX is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check CATX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BSX's ROE is +0.15%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BSX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BSX.Check SMLR's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, TMCI has a market cap of 308.8M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while TMCI trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas TMCI's P/E ratio is -5.06. In terms of profitability, BSX's ROE is +0.15%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BSX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TMCI's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, SENS has a market cap of 293.4M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while SENS trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas SENS's P/E ratio is -3.51. In terms of profitability, BSX's ROE is +0.15%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BSX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check SENS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ANIK trades at $21.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ANIK's P/E ratio is 43.71. In terms of profitability, BSX's ROE is +0.15%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, BSX is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for BSX.Check ANIK's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, PROF has a market cap of 269.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while PROF trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas PROF's P/E ratio is -5.98. In terms of profitability, BSX's ROE is +0.15%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BSX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BSX.Check PROF's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, RXST has a market cap of 259.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while RXST trades at $6.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas RXST's P/E ratio is -6.73. In terms of profitability, BSX's ROE is +0.15%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BSX is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BSX.Check RXST's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BSX's ROE is +0.15%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BSX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BSX.Check MGRM's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, FOCL has a market cap of 233.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while FOCL trades at $6.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas FOCL's P/E ratio is -8.00. In terms of profitability, BSX's ROE is +0.15%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, BSX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check FOCL's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BSX's ROE is +0.15%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BSX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BSX.Check NVRO's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, TLSI has a market cap of 212.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while TLSI trades at $5.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas TLSI's P/E ratio is -3.34. In terms of profitability, BSX's ROE is +0.15%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BSX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check TLSI's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, RCEL has a market cap of 193M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while RCEL trades at $7.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas RCEL's P/E ratio is -4.95. In terms of profitability, BSX's ROE is +0.15%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BSX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BSX.Check RCEL's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BSX's ROE is +0.15%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BSX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check BSGM's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, QTRX has a market cap of 189.8M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while QTRX trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas QTRX's P/E ratio is -2.52. In terms of profitability, BSX's ROE is +0.15%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, BSX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BSX.Check QTRX's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BSX's ROE is +0.15%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BSX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BSX.Check MDGS's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, STIM has a market cap of 165.6M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while STIM trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas STIM's P/E ratio is -4.41. In terms of profitability, BSX's ROE is +0.15%, compared to STIM's ROE of -1.65%. Regarding short-term risk, BSX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BSX.Check STIM's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, INGN has a market cap of 163.8M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while INGN trades at $6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas INGN's P/E ratio is -6.65. In terms of profitability, BSX's ROE is +0.15%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BSX is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BSX.Check INGN's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BSX's ROE is +0.15%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BSX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BSX.Check QIPT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BSX's ROE is +0.15%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BSX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BSX.Check ICAD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, OWLT has a market cap of 99.9M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while OWLT trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas OWLT's P/E ratio is -39.43. In terms of profitability, BSX's ROE is +0.15%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, BSX is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check OWLT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while LUCD trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas LUCD's P/E ratio is -2.61. In terms of profitability, BSX's ROE is +0.15%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, BSX is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BSX.Check LUCD's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, HSDT has a market cap of 98.7M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while HSDT trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas HSDT's P/E ratio is -0.02. In terms of profitability, BSX's ROE is +0.15%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, BSX is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for BSX.Check HSDT's competition here

Boston Scientific Corporation (NYSE: BSX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BSX stands at 73.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BSX is priced at $49.31 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BSX currently has a P/E ratio of 15.91, whereas HJLI's P/E ratio is N/A. In terms of profitability, BSX's ROE is +0.15%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BSX is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BSX.Check HJLI's competition here